Cure My Disease

Don't miss your cure!

 Log in / Sign up

Electric shocks boost drug to shrink blood vessel tangles

NCT ID NCT07579962

Disease control Sponsor: Institute of Oncology Ljubljana Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new treatment called bleomycin electrosclerotherapy (BEST) for low-flow vascular malformations—abnormal clusters of blood or lymph vessels. The approach combines an injected drug (bleomycin) with brief electrical pulses to make the drug work better. Researchers will enroll 140 adults whose malformations didn't respond well to prior treatments, and they'll measure changes in lesion size using MRI at 3 and 12 months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Bleomycin (a chemotherapy drug) injected into the malformation, followed by electrical pulses to boost its effect
What this could lead to
If it works, this could offer a more effective, less invasive treatment option for people with hard-to-treat vascular malformations, potentially reducing the need for surgery.
What could go wrong
This is a phase 2 trial with only 140 participants, so results are preliminary. The treatment involves bleomycin, which can have side effects like skin changes or lung issues, and the electrical pulses may cause discomfort or local reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 140 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age ≥ 18 * patients with low-flow vascular malformations (venous, lymphatic, capillary or mixed type malformations), * patients with a low-flow vascular malformation poorly responding or recurring after previous treatment(s), * longer lesion diameter not exceeding 25 cm. * more than one lesion can be treated. The limiting factor is the maximal dose per patient per treatment session; 10 000 IU in adults, * skin or mucosal, superficial or deep-seated lesions can be treated, * technical feasibility of the BEST procedure, i.e.: injection of bleomycin and safe placement of electrodes into the vascular malformation are technically feasible. Exclusion Criteria: * pregnancy and lactation, * women of childbearing potential and men not using reliable contraception, * in adults, previous bleomycin exposure with a cumulative dose greater than 100 000 IU. In case of abnormal respiratory results/chest pathology (including previous severe or long COVID) in consultation with a pulmonologist, special care is required, and bleomycin exposure may be contraindicated, * known allergy or hypersensitivity to bleomycin, * presence of significant central venous drainage precluding sclerotherapy, * acute lung infection or severely reduced lung function, * bleomycin-related lung toxicity or reduced lung function which can indicate bleomycin-related lung toxicity, * ataxia telangiectasia, * chronic renal dysfunction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Vascular malformations are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vascular malformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Vascular malformations

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.